Clinical Trial Update: Effective Dosing of Burosumab in XLH

View source ↗

Summary

This clinical trial update addresses effective dosing of burosumab for X-linked hypophosphatemia and is currently recruiting at the University of Nottingham.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• Crysvita (burosumab)

Snippet

Sponsor: University of Nottingham | Conditions: X-linked Hypophosphatemia (XLH) | Status: RECRUITING